Lifesign 200019 - Status BTA Control Set, 2 x 2 mL, 1/BX
Status BTA Control Set
A Rapid Test For the Qualitative Detection of Bladder Tumor Associated Antigen in Human Urine. A Rapid Test For the Qualitative Detection of Bladder Tumor Associated Antigen in Human Urine of Patients Diagnosed with Bladder Cancer
- CLIA Waived
- Results in 5 minutes
- Simple procedure requires adding 3 drops of urine to test device; no sample preparation needed
- Accurate test results with superior sensitivity and specificity
- Detects early stage recurrence cancer that cytology1 may miss
Content Of Status BTA Test Package
The Status BTA Test Device
Tumor markers are substances found in the blood, urine, stool, other body fluids, or tissues of some cancer patients. Tumor markers may be used to help diagnose cancer, predict a patients response to certain cancer therapies, check a patients response to treatment, or determine whether cancer has returned3. Because tumor markers can be used to assess the response of a tumor to treatment and for prognosis, rapid screening tests like the Status BTA product are very helpful in the treatment management of cancer patients.
The Status BTA test is an in vitro immunoassay intended for the qualitative detection of bladder tumor associated antigen in urine of persons diagnosed with bladder cancer. The test is indicated for use as an aid in the management of bladder cancer patients in conjunction with cystoscopy. The simple urine sample collection also allows for improved patient comfort. Patients with previous diagnosis of bladder cancer have been routinely followed for recurrence by urine cytology and cystoscopy but both methods have their limitations.
